Immunotherapy for a POLE Mutation Advanced Non-Small-Cell Lung Cancer Patient

被引：8

作者：

Fu, Yang ^{[1
]}

Zheng, Yue ^{[1
]}

Wang, Pei-Pei ^{[1
]}

Chen, Yue-Yun ^{[1
]}

Ding, Zhen-Yu ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Canc Ctr, West China Med Sch,Dept Bibtherapy,State Key Lab, Chengdu, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

关键词：

POLE mutation; lung adenocarcinoma; PD-L1; brain metastases; CR; COLORECTAL-CANCER; PD-1; BLOCKADE; OPEN-LABEL; BRAIN; PEMBROLIZUMAB; CHEMOTHERAPY; NSCLC;

D O I：

10.3389/fphar.2022.817265

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Currently, the predictive role of POLE mutations for immunotherapy is under intense investigation. The POLE gene encodes one of the four subunits of DNA polymerase important for DNA replication and repair. POLE mutations are related to other favorable predicative factors such as high expression of PD-L1, high TMB, and infiltration of CD8(+) cells in the tumor microenvironment. No formal clinical trials studied the efficacy of immunotherapy in lung patients harboring POLE mutation, and only few cases were mentioned in the literature. Moreover, lung cancer patients are prone to brain metastasis, which is notorious for the unresponsiveness to chemotherapy. The efficacy of immunotherapy for brain metastasis is still controversial. Here, we described a case of a POLEmt non-small-cell lung cancer (NSCLC) patient with brain metastasis who was treated with immunotherapy. His brain lesions disappeared after treatment. Our report strongly supported the benefit of immune-combined therapy for advanced NSCLC patients with POLE mutation, even with brain metastasis.

引用

页数：6

共 23 条

[1] Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study [J].

Besse, Benjamin ;

Le Moulec, Sylvestre ;

Mazieres, Julien ;

Senellart, Helene ;

Barlesi, Fabrice ;

Chouaid, Christos ;

Dansin, Eric ;

Berard, Henri ;

Falchero, Lionel ;

Gervais, Radj ;

Robinet, Gilles ;

Ruppert, Anne-Marie ;

Schott, Roland ;

Lena, Herve ;

Clement-Duchene, Christelle ;

Quantin, Xavier ;

Souquet, Pierre Jean ;

Tredaniel, Jean ;

Moro-Sibilot, Denis ;

Perol, Maurice ;

Madroszyk, Anne-Catherine ;

Soria, Jean-Charles .

CLINICAL CANCER RESEARCH, 2015, 21 (08) :1896-1903

[2] Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study [J].

Domingo, Enric ;

Freeman-Mills, Luke ;

Rayner, Emily ;

Glaire, Mark ;

Briggs, Sarah ;

Vermeulen, Louis ;

Fessler, Evelyn ;

Medema, Jan Paul ;

Boot, Arnoud ;

Morreau, Hans ;

van Wezel, Tom ;

Liefers, Gerrit-Jan ;

Lothe, Ragnhild A. ;

Danielsen, Stine A. ;

Sveen, Anita ;

Nesbakken, Arild ;

Zlobec, Inti ;

Lugli, Alessandro ;

Koelzer, Viktor H. ;

Berger, Martin D. ;

Casteilvi-Bel, Sergi ;

Munoz, Jenifer ;

de Bruyn, Marco ;

Nijman, Hans W. ;

Novelli, Marco ;

Lawson, Kay ;

Oukrif, Dahtnane ;

Frangou, Eleni ;

Dutton, Peter ;

Tejpar, Sabine ;

Delorenzi, Mauro ;

Kerr, Rachel ;

Kerr, David ;

Tomlinson, Ian ;

Church, David N. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2016, 1 (03) :207-216

[3] Atezolizumab in patients with advanced non -small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study [J].

Gadgeel, Shirish M. ;

Lukas, Rimas, V ;

Goldschmidt, Jerome ;

Conkling, Paul ;

Park, Keunchil ;

Cortinovis, Diego ;

de Marinis, Filippo ;

Rittmeyer, Achim ;

Patel, Jyoti D. ;

von Pawel, Joachim ;

O'Hear, Carol ;

Lai, Catherine ;

Hu, Sylvia ;

Ballinger, Marcus ;

Sandler, Alan ;

Gandhi, Mayank ;

Fehrenbacher, Lou .

LUNG CANCER, 2019, 128 :105-112

[4] Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial [J].

Goldberg, Sarah B. ;

Schalper, Kurt A. ;

Gettinger, Scott N. ;

Mahajan, Amit ;

Herbst, Roy S. ;

Chiang, Anne C. ;

Lilenbaum, Rogerio ;

Wilson, Frederick H. ;

Omay, Sacit Bulent ;

Yu, James B. ;

Jilaveanu, Lucia ;

Thuy Tran ;

Pavlik, Kira ;

Rowen, Elin ;

Gerrish, Heather ;

Komlo, Annette ;

Gupta, Richa ;

Wyatt, Hailey ;

Ribeiro, Matthew ;

Kluger, Yuval ;

Zhou, Geyu ;

Wei, Wei ;

Chiang, Veronica L. ;

Kluger, Harriet M. .

LANCET ONCOLOGY, 2020, 21 (05) :655-663

[5] Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial [J].

Goldberg, Sarah B. ;

Gettinger, Scott N. ;

Mahajan, Amit ;

Chiang, Anne C. ;

Herbst, Roy S. ;

Sznol, Mario ;

Tsiouris, Apostolos John ;

Cohen, Justine ;

Vortmeyer, Alexander ;

Jilaveanu, Lucia ;

Yu, James ;

Hegde, Upendra ;

Speaker, Stephanie ;

Madura, Matthew ;

Ralabate, Amanda ;

Rivera, Angel ;

Rowen, Elin ;

Gerrish, Heather ;

Yao, Xiaopan ;

Chiang, Veronica ;

Kluger, Harriet M. .

LANCET ONCOLOGY, 2016, 17 (07) :976-983

[6] Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a POLE. Mutation [J].

Gong, Jun ;

Wang, Chongkai ;

Lee, Peter P. ;

Chu, Peiguo ;

Fakih, Marwan .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (02) :142-147

[7] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

[8] Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 [J].

Howitt, Brooke E. ;

Shukla, Sachet A. ;

Sholl, Lynette M. ;

Ritterhouse, Lauren L. ;

Watkins, Jaclyn C. ;

Rodig, Scott ;

Stover, Elizabeth ;

Strickland, Kyle C. ;

D'Andrea, Alan D. ;

Wu, Catherine J. ;

Matulonis, Ursula A. ;

Konstantinopoulos, Panagiotis A. .

JAMA ONCOLOGY, 2015, 1 (09) :1319-1323

[9] Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy [J].

Johanns, Tanner M. ;

Miller, Christopher A. ;

Dorward, Ian G. ;

Tsien, Christina ;

Chang, Edward ;

Perry, Arie ;

Uppaluri, Ravindra ;

Ferguson, Cole ;

Schmidt, Robert E. ;

Dahiya, Sonika ;

Ansstas, George ;

Mardis, Elaine R. ;

Dunn, Gavin P. .

CANCER DISCOVERY, 2016, 6 (11) :1230-1236

[10] A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer [J].

Kim, Jwa Hoon ;

Kim, Sun Young ;

Baek, Ji Yeon ;

Cha, Yong Jun ;

Ahn, Joong Bae ;

Kim, Han Sang ;

Lee, Keun-Wook ;

Kim, Ji-Won ;

Kim, Tae-You ;

Chang, Won Jin ;

Park, Joon Oh ;

Kim, Jihun ;

Kim, Jeong Eun ;

Hong, Yong Sang ;

Kim, Yeul Hong ;

Kim, Tae Won .

CANCER RESEARCH AND TREATMENT, 2020, 52 (04) :1135-1144

← 1 2 3 →